Oruka Therapeutics, Inc. (ORKA) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 129.03M USD | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | 28.53M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -155.08M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $129.03M | (m) | $28.53M | $-155.08M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $109.86M | (m) | $26.32M | $-133.40M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $100.64M | (m) | $24.24M | $-122.05M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $26.03M | (m) | $9.37M | $-36.64M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $664.00K | $0.00 | $521.00K | $-9.13M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $788.00K | $0.00 | $596.00K | $-7.98M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $1.01M | $0.00 | $686.00K | $-7.30M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $1.03M | $0.00 | $665.00K | $-7.25M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $1.73M | $0.00 | $608.00K | $-7.87M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $2.96M | $0.00 | $593.00K | $-9.12M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $4.75M | $0.00 | $556.00K | $-10.60M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $8.63M | $0.00 | $555.00K | $-14.73M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $11.04M | $0.00 | $562.00K | $-16.89M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $13.13M | $0.00 | $523.00K | $-18.51M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $13.83M | $0.00 | $497.00K | $-19.34M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $13.10M | $0.00 | $396.00K | $-18.78M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $10.71M | $0.00 | $297.00K | $-16.05M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $7.50M | $0.00 | $168.00K | $-12.53M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $4.99M | $0.00 | $43.00K | $-9.77M | $9.00K | (m) | (m) | -1085.11× | Reported |
| 2020-09-30 | $2.17M | $0.00 | $52.00K | $-5.92M | $9.00K | (m) | (m) | -657.56× | Reported |
| 2020-06-30 | $1.47M | $0.00 | $76.00K | $-5.17M | $8.00K | (m) | (m) | -646.88× | Reported |
| 2020-03-31 | $1.54M | $0.00 | $117.00K | $-5.37M | $8.00K | (m) | (m) | -671.63× | Reported |
| 2019-12-31 | $1.83M | $0.00 | $151.00K | $-5.81M | $7.00K | (m) | (m) | -830.57× | Reported |
| 2019-09-30 | $2.07M | $0.00 | $182.00K | $-6.06M | $7.00K | (m) | (m) | -866.14× | Reported |
| 2019-06-30 | $2.47M | $0.00 | $211.00K | $-6.48M | $8.00K | (m) | (m) | -809.75× | Reported |
| 2019-03-31 | $3.18M | $0.00 | $226.00K | $-7.13M | $8.00K | (m) | (m) | -890.75× | Reported |
| 2018-12-31 | $4.24M | $0.00 | $273.00K | $-8.12M | $8.00K | (m) | (m) | -1014.75× | Reported |
| 2018-09-30 | $6.45M | $0.00 | $334.00K | $-10.89M | $8.00K | (m) | (m) | -1361.00× | Reported |
| 2018-06-30 | $9.20M | $0.00 | $395.00K | $-13.70M | $8.00K | (m) | (m) | -1712.63× | Reported |
| 2018-03-31 | $12.55M | $0.00 | $454.00K | $-17.10M | $7.00K | (m) | (m) | -2443.43× | Reported |
| 2017-12-31 | $14.08M | $0.00 | $458.00K | $-18.71M | $6.00K | (m) | (m) | -3118.67× | Reported |
| 2017-09-30 | $14.36M | $0.00 | $310.00K | $-18.71M | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $14.60M | $0.00 | $458.00K | $-18.94M | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $13.00M | $0.00 | $522.00K | $-17.33M | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $12.35M | $0.00 | $576.00K | $-16.61M | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | $11.12M | $0.00 | $750.00K | $-15.50M | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | $9.12M | $0.00 | $632.00K | $-13.60M | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | $7.95M | $0.00 | $624.00K | $-12.38M | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $7.06M | $0.00 | $599.00K | $-11.46M | $4.00K | (m) | (m) | -2863.75× | Reported |
| 2015-09-30 | $6.75M | (m) | $610.00K | $-10.89M | $4.00K | (m) | (m) | -2723.00× | Reported |
| 2015-06-30 | $6.37M | (m) | $622.00K | $-10.36M | $4.00K | (m) | (m) | -2590.00× | Reported |
| 2015-03-31 | $6.02M | (m) | $619.00K | $-10.05M | $3.00K | (m) | (m) | -3349.00× | Reported |
| 2014-12-31 | $5.63M | $0.00 | $647.00K | $-9.69M | $3.00K | (m) | (m) | -3231.00× | Reported |
| 2014-09-30 | $5.83M | (m) | $649.00K | $-10.03M | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | $5.21M | (m) | $537.00K | $-9.47M | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | $4.05M | (m) | $399.00K | $-8.26M | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $2.93M | (m) | $283.00K | $-6.94M | (m) | (m) | (m) | (m) | (m) |
| 2013-09-30 | $1.33M | (m) | $188.00K | $-4.83M | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | $775.00K | (m) | $214.00K | $-4.04M | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | $851.00K | (m) | $257.00K | $-3.98M | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $1.09M | (m) | $306.00K | $-4.32M | (m) | (m) | (m) | (m) | (m) |
| 2012-09-30 | $1.50M | (m) | $319.00K | $-5.11M | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | $1.87M | (m) | $323.00K | $-6.01M | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | $2.05M | (m) | $321.00K | $-6.57M | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | $2.31M | (m) | $308.00K | $-7.36M | (m) | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | (m) | $353.00K | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | $387.00K | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | $458.00K | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | $845.00K | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | $545.00K | (m) | (m) | (m) | (m) | (m) | (m) |
| 2007-12-31 | (m) | (m) | $50.00K | (m) | (m) | (m) | (m) | (m) | (m) |
| 2006-12-31 | (m) | (m) | $39.00K | (m) | (m) | (m) | (m) | (m) | (m) |
| 2003-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Veradermics, Inc (MANE) | United States | $4.839B |